A monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor

Virology Journal

Eric S Rosenberg¹  Sue Bazner¹  Graham McGrath¹  Lindsay Jones¹  Jenna Rychert¹ 

[1] Departments of Medicine and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

关键词: Monoclonal antibody therapy;    LFA-1;    HIV-1;   

Others  :  1150797
DOI  :  10.1186/1743-422X-10-120

 received in 2012-12-13, accepted in 2013-04-12,  发布年份 2013

【 摘 要 】

Background

Lymphocyte Function-Associated Antigen-1 (LFA-1) likely plays a role in the pathogenesis of against HIV-1 and is known to facilitate cell-to-cell transmission of the virus. A monoclonal antibody specific for LFA-1 (Cytolin®) was evaluated as a potential therapeutic in pilot studies performed in the mid-1990s. These uncontrolled human studies suggested that administration of this anti-LFA-1 antibody to HIV-1 infected individuals could provide a modest benefit by decreasing circulating HIV-1 RNA and increasing CD4+ T cell counts. At the time, it was proposed that when bound to cytolytic T cells, the antibody inhibited lysis of activated CD4+ T cells. Given the renewed interest in monoclonal antibody therapy for HIV-1 infected individuals, we investigated possible mechanisms of action of this antibody in vitro.

Methods

To assess whether this anti-LFA-1 antibody binds to HIV-1, a virus capture assay was performed. Binding of the antibody to cells was assessed using flow cytometry. Inhibition of HIV-1 replication was determined in culture by measuring the amount of p24 produced by ELISA. After co-culture of the antibody with peripheral blood mononuclear cells, supernatants were assayed for cytokines and chemokines using various immunoassays.

Results

Our experiments demonstrate that anti-LFA-1 antibody binds to CCR5 and CXCR4 utilizing strains of HIV-1. It also binds to CD8+ T cells and dendritic cells. When bound to virus prior to infection, there is no decrease in HIV-1 replication, suggesting it does not directly inhibit viral replication via virus binding. When bound to cells, it does not inhibit lysis of CD4+ T cells, as was originally hypothesized. Binding to cells does appear to induce the production of a soluble factor that inhibits HIV-1 replication. We determined that this soluble factor was not any of the cytokines or chemokines with known anti-HIV-1 activity. Further, the antibody does not appear to induce any common immune modulating cytokines or chemokines.

Conclusions

These results suggest that one possible mechanism of action of this anti-LFA-1 antibody is to inhibit HIV-1 replication via the production of a soluble antiviral factor that is induced upon binding to cells.

【 授权许可】

   
2013 Rychert et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bastiani L, Laal S, Kim M, Zolla-Pazner S: Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997, 71:3444-3450.
• [2]Jolly C, Mitar I, Sattentau QJ: Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J Virol 2007, 81:13916-13921.
• [3]Morimoto C, Rudd CE, Letvin NL, Schlossman SF: A novel epitope of the LFA-1 antigen which can distinguish killer effector and suppressor cells in human CD8 cells. Nature 1987, 330:479-482.
• [4]Cavallin F, Traldi A, Zambello R: Phenotypical and functional evaluation of CD8+/S6F1+ T lymphocytes in haemophiliac individuals with HIV-1 infection. Clin Exp Immunol 1993, 93:51-55.
• [5]Fauce SR, Yang OO, Effros RB: Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-1 infected persons. J Immunol Methods 2007, 327:75-81.
• [6]Watret KC, Whitelaw JA, Froebel KS, Bird AG: Phenotypic characterization of CD8+ T cell populations in HIV-1 disease and in anti-HIV immunity. Clin Exp Immunol 1993, 92:93-99.
• [7]Allen AD, Hart DN, Hechinger MK, Slattery MJ, Chesson CV, Vidikan P: Leukocyte adhesion molecules as a cofactor in AIDS: basic science and pilot study. Medical hypotheses 1995, 45:164-168.
• [8]Allen AD, Hillis T, Vidikan P, Beer V: Pitfalls in the use of surrogate markers for human immunodeficiency virus disease: further evidence on pathogenesis. Medical hypotheses 1996, 47:27-30.
• [9]Grant MD, Smaill FM, Rosenthal KL: Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-1 infected individuals. Clin Exp Immunol 1993, 93:356-362.
• [10]Zarling JM, Ledbetter JA, Sias J, Fultz P, Eichberg J, Gjerset G, Moran PA: HIV-1 infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. J Immunol 1990, 144:2992-2998.
• [11]Lub M, Van Kooyk Y, Figdor CG: Ins and outs of LFA-1. Immunol Today 1995, 16:479-483.
• [12]Fan ST, Edgington TS: Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 1993, 150:2972-2980.
• [13]Levy JA: The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003, 24:628-632.
• [14]Mackewicz CE, Ortega H, Levy JA: Effect of cytokines on HIV-1 replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol 1994, 153:329-343.
• [15]Vella C, Daniels RS: CD8+ T-cell-mediated non-cytolytic suppression of human immuno-deficiency viruses. Curr Drug Targets Infect Disord 2003, 3:97-113.
• [16]Xingyuan M, Wenyun Z, Tianwen W: Leukocyte function-associated antigen-1: structure, function and application prospects. Protein Pept Lett 2006, 13:397-400.
• [17]Tardif MR, Tremblay MJ: Regulation of LFA-1 activity through cytoskeleton remodeling and signaling components modulates the efficiency of HIV-1 type-1 entry in activated CD4+ T lymphocytes. J Immunol 2005, 175:926-935.
• [18]Hioe CE, Tuen M, Vasiliver-Shamis G, Alvarez Y, Prins KC, Banerjee S, Nadas A, Cho MW, Dustin ML, Kachlany SC: HIV-1 envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA). PLoS One 2011, 6:e23202.
• [19]Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA: HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008, 9:301-309.
• [20]Walker CM, Levy JA: A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV-1 replication. Immunology 1989, 66:628-630.
• [21]Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL: Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 2010, 207:763-776.
• [22]Nyambi PN, Gorny MK, Bastiani L, van der Groen G, Williams C, Zolla-Pazner S: Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998, 72:9384-9391.
• [23]Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, Zolla-Pazner S: Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 2000, 74:7096-7107.
• [24]Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, Robinson J, van der Groen G, Quinnan GV Jr: Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology 2006, 347:36-51.
• [25]Moore JP, McCutchan FE, Poon SW, Mascola J, Liu J, Cao Y, Ho DD: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994, 68:8350-8364.
• [26]Robinson JE, Elliott DH, Martin EA, Micken K, Rosenberg ES: High frequencies of antibody responses to CD4 induced epitopes in HIV-1 infected patients started on HAART during acute infection. Hum Antibodies 2005, 14:115-121.
• [27]Tuen M, Visciano ML, Chien PC Jr, Cohen S, Chen PD, Robinson J, He Y, Pinter A, Gorny MK, Hioe CE: Characterization of antibodies that inhibit HIV-1 gp120 antigen processing and presentation. Eur J Immunol 2005, 35:2541-2551.